113 POSTER Phase II trial to assess the activity of MVA5T4 (Trovax®) alone versus MVA5T4 plus granulocyte macrophage colony-stimulating factor (GM-CSF) in patients (pts) with progressive hormone refractory prostate cancer (HRPC)
- Resource Type
- Abstract
- Source
- In
EJC Supplements 2006 4(12):38-38 - Subject
- Language
- ISSN
- 1359-6349